InterMune to Present at Oppenheimer Conference

BRISBANE, Calif., Oct. 29 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq:
ITMN) today announced that Dan Welch, Chairman, Chief Executive Officer and
President of InterMune, will present at the Oppenheimer 20th Annual Healthcare
Conference in New York on November 4, 2009 at 3:20 p.m. EST.

To access a live audio webcast of the presentation, investors and other
interested parties may log on to the investor relations page of InterMune's
corporate website at www.intermune.com. The company recommends logging on to
the site 15 minutes prior to the start of the presentation in order to
register or download any necessary software.

About InterMune
InterMune is a biotechnology company focused on the research, development and
commercialization of innovative therapies in pulmonology and hepatology.
InterMune has an R&D portfolio addressing idiopathic pulmonary fibrosis (IPF)
and hepatitis C virus (HCV) infections. The pulmonology portfolio includes
pirfenidone for which a Phase 3 program in patients with IPF (CAPACITY) has
been completed and the compound is currently in the pre-registration stage.
The company also has a research program focused on a pirfenidone analog named
ITMN-520. The hepatology portfolio includes the HCV protease inhibitor
compound ITMN-191 (referred to as RG7227 at Roche) that entered Phase 2b in
August of 2009 and a second-generation HCV protease inhibitor research
program. For additional information about InterMune and its R&D pipeline,
please visit www.intermune.com.

SOURCE InterMune, Inc.

Jim Goff of InterMune, Inc., +1-415-466-2228, jgoff@intermune.com